December 22, 2014 12:40 AM ET

Pharmaceuticals

Company Overview of Ludwig Institute for Cancer Research Ltd.

Company Overview

Ludwig Institute for Cancer Research Ltd., a non-profit research institute, focuses to improve the understanding and control of cancer. Its activities include investigator-initiated work to understand how and why cancer onset and progression occur; and exploring the prognostic, diagnostic, and/or therapeutic potential of its discoveries by conducting clinical research in the human setting. The company also engages in exploring therapeutic modalities that include cancer vaccines, targeted antibodies, enzymatic depletion, small molecule inhibitors, and siRNAs. Ludwig Institute for Cancer Research Ltd. was founded in 1971 and is based in New York, New York. It has research sites in Brussels, Be...

605 Third Avenue

28th Floor

New York, NY 10017

United States

Founded in 1971

Phone:

212-450-1500

Fax:

212-450-1565

Key Executives for Ludwig Institute for Cancer Research Ltd.

Chief Executive Officer
Chief Financial Officer and Secretary
Executive Director of Operations
Executive Director of Technology Development
Director of Communications
Compensation as of Fiscal Year 2014.

Ludwig Institute for Cancer Research Ltd. Key Developments

4-Antibody AG Enters into License Agreement with Ludwig Institute for Cancer Research Ltd

4-Antibody AG entered into a License Agreement with the Ludwig Institute for Cancer Research Ltd. which replaces and supersedes the Collaborative Research and Development Agreement entered into between the parties on May 23, 2011. Pursuant to the terms of the License Agreement, Ludwig granted 4AB an exclusive, worldwide license under certain intellectual property rights of Ludwig and Memorial Sloan Kettering Cancer Center arising from the Prior Agreement to further develop and commercialize GITR, OX-40 and TIM-3 antibodies. Pursuant to the License Agreement, 4AB is obligated to make an upfront payment of $1 million to Ludwig. The License Agreement also obligates 4AB to make potential milestone payments of up to $20 million for events prior to regulatory approval of licensed products, and potential milestone payments in excess of $80 million if licensed products are approved in multiple jurisdictions, in more than one indication, and certain sales milestones are achieved. 4AB will also be obligated to pay low to mid-single digit royalties on all net sales of licensed products during the royalty period, and to pay Ludwig a percentage of any sublicensing income, ranging from a low to mid-double digit percentage depending on various factors. The License Agreement may be terminated as follows: by either party if the other party commits a material, uncured breach; by either party if the other party initiates bankruptcy, liquidation or similar proceedings; or by 4AB for convenience upon 90 days' prior written notice.

Similar Private Companies By Industry

Company Name Region
QPS, L.L.C. United States
Wincott & Associates, LLC United States
Jason Enterprises, Inc. United States
Therapeutic Discovery Corporation United States
NutraCea/Cura, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ludwig Institute for Cancer Research Ltd., please visit www.licr.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.